Literature DB >> 19878682

Identification of novel peptide substrates for protein farnesyltransferase reveals two substrate classes with distinct sequence selectivities.

James L Hougland1, Katherine A Hicks, Heather L Hartman, Rebekah A Kelly, Terry J Watt, Carol A Fierke.   

Abstract

Prenylation is a posttranslational modification essential for the proper localization and function of many proteins. Farnesylation, the attachment of a 15-carbon farnesyl group near the C-terminus of protein substrates, is catalyzed by protein farnesyltransferase (FTase). Farnesylation has received significant interest as a target for pharmaceutical development, and farnesyltransferase inhibitors are in clinical trials as cancer therapeutics. However, as the total complement of prenylated proteins is unknown, the FTase substrates responsible for farnesyltransferase inhibitor efficacy are not yet understood. Identifying novel prenylated proteins within the human proteome constitutes an important step towards understanding prenylation-dependent cellular processes. Based on sequence preferences for FTase derived from analysis of known farnesylated proteins, we selected and screened a library of small peptides representing the C-termini of 213 human proteins for activity with FTase. We identified 77 novel FTase substrates that exhibit multiple-turnover (MTO) reactivity within this library; our library also contained 85 peptides that can be farnesylated by FTase only under single-turnover (STO) conditions. Based on these results, a second library was designed that yielded an additional 29 novel MTO FTase substrates and 45 STO substrates. The two classes of substrates exhibit different specificity requirements. Efficient MTO reactivity correlates with the presence of a nonpolar amino acid at the a(2) position and a Phe, Met, or Gln at the terminal X residue, consistent with the proposed Ca(1)a(2)X sequence model. In contrast, the sequences of the STO substrates vary significantly more at both the a(2) and the X residues and are not well described by current farnesylation algorithms. These results improve the definition of prenyltransferase substrate specificity, test the efficacy of substrate algorithms, and provide valuable information about therapeutic targets. Finally, these data illuminate the potential for in vivo regulation of prenylation through modulation of STO versus MTO peptide reactivity with FTase.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19878682      PMCID: PMC2916699          DOI: 10.1016/j.jmb.2009.10.038

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  63 in total

1.  Characterization of RAC3, a novel member of the Rho family.

Authors:  L Haataja; J Groffen; N Heisterkamp
Journal:  J Biol Chem       Date:  1997-08-15       Impact factor: 5.157

2.  Mechanistic studies of rat protein farnesyltransferase indicate an associative transition state.

Authors:  C Huang; K E Hightower; C A Fierke
Journal:  Biochemistry       Date:  2000-03-14       Impact factor: 3.162

3.  Substrate binding is required for release of product from mammalian protein farnesyltransferase.

Authors:  W R Tschantz; E S Furfine; P J Casey
Journal:  J Biol Chem       Date:  1997-04-11       Impact factor: 5.157

4.  Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo.

Authors:  C A Rowell; J J Kowalczyk; M D Lewis; A M Garcia
Journal:  J Biol Chem       Date:  1997-05-30       Impact factor: 5.157

Review 5.  Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras?

Authors:  A D Cox; C J Der
Journal:  Biochim Biophys Acta       Date:  1997-08-08

6.  Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice.

Authors:  Z Chen; J Sun; A Pradines; G Favre; J Adnane; S M Sebti
Journal:  J Biol Chem       Date:  2000-06-16       Impact factor: 5.157

Review 7.  Enzymology and biology of CaaX protein prenylation.

Authors:  H W Fu; P J Casey
Journal:  Recent Prog Horm Res       Date:  1999

8.  K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors.

Authors:  D B Whyte; P Kirschmeier; T N Hockenberry; I Nunez-Oliva; L James; J J Catino; W R Bishop; J K Pai
Journal:  J Biol Chem       Date:  1997-05-30       Impact factor: 5.157

9.  A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines.

Authors:  L Sepp-Lorenzino; Z Ma; E Rands; N E Kohl; J B Gibbs; A Oliff; N Rosen
Journal:  Cancer Res       Date:  1995-11-15       Impact factor: 12.701

10.  Context-dependent substrate recognition by protein farnesyltransferase.

Authors:  James L Hougland; Corissa L Lamphear; Sarah A Scott; Richard A Gibbs; Carol A Fierke
Journal:  Biochemistry       Date:  2009-03-03       Impact factor: 3.162

View more
  34 in total

1.  Finding a needle in the haystack: computational modeling of Mg2+ binding in the active site of protein farnesyltransferase.

Authors:  Yue Yang; Dhruva K Chakravorty; Kenneth M Merz
Journal:  Biochemistry       Date:  2010-11-09       Impact factor: 3.162

2.  Structures of Cryptococcus neoformans protein farnesyltransferase reveal strategies for developing inhibitors that target fungal pathogens.

Authors:  Michael A Hast; Connie B Nichols; Stephanie M Armstrong; Shannon M Kelly; Homme W Hellinga; J Andrew Alspaugh; Lorena S Beese
Journal:  J Biol Chem       Date:  2011-08-04       Impact factor: 5.157

3.  Evaluation of alkyne-modified isoprenoids as chemical reporters of protein prenylation.

Authors:  Amanda J DeGraw; Charuta Palsuledesai; Joshua D Ochocki; Jonathan K Dozier; Stepan Lenevich; Mohammad Rashidian; Mark D Distefano
Journal:  Chem Biol Drug Des       Date:  2010-10-11       Impact factor: 2.817

4.  The chaperone SmgGDS-607 has a dual role, both activating and inhibiting farnesylation of small GTPases.

Authors:  Desirée García-Torres; Carol A Fierke
Journal:  J Biol Chem       Date:  2019-06-13       Impact factor: 5.157

Review 5.  Recent advances in protein prenyltransferases: substrate identification, regulation, and disease interventions.

Authors:  Elaina A Zverina; Corissa L Lamphear; Elia N Wright; Carol A Fierke
Journal:  Curr Opin Chem Biol       Date:  2012-11-08       Impact factor: 8.822

6.  Expansion of protein farnesyltransferase specificity using "tunable" active site interactions: development of bioengineered prenylation pathways.

Authors:  James L Hougland; Soumyashree A Gangopadhyay; Carol A Fierke
Journal:  J Biol Chem       Date:  2012-09-19       Impact factor: 5.157

7.  Exploration of GGTase-I substrate requirements. Part 1: Synthesis and biochemical evaluation of novel aryl-modified geranylgeranyl diphosphate analogs.

Authors:  Kayla J Temple; Elia N Wright; Carol A Fierke; Richard A Gibbs
Journal:  Bioorg Med Chem Lett       Date:  2016-06-16       Impact factor: 2.823

8.  Protein Lipidation: Occurrence, Mechanisms, Biological Functions, and Enabling Technologies.

Authors:  Hong Jiang; Xiaoyu Zhang; Xiao Chen; Pornpun Aramsangtienchai; Zhen Tong; Hening Lin
Journal:  Chem Rev       Date:  2018-01-02       Impact factor: 60.622

9.  A combination of metabolic labeling and 2D-DIGE analysis in response to a farnesyltransferase inhibitor facilitates the discovery of new prenylated proteins.

Authors:  Charuta C Palsuledesai; Joshua D Ochocki; Todd W Markowski; Mark D Distefano
Journal:  Mol Biosyst       Date:  2014-05

10.  Exploration of GGTase-I substrate requirements. Part 2: Synthesis and biochemical analysis of novel saturated geranylgeranyl diphosphate analogs.

Authors:  Kayla J Temple; Elia N Wright; Carol A Fierke; Richard A Gibbs
Journal:  Bioorg Med Chem Lett       Date:  2016-06-15       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.